Intelligent Clinical Trials 2024

Without an AI revolution in clinical development, the world’s health is at risk3 Using generative AI to optimize clinical trials is both a moral and financial imperative. Global healthcare systems face soaring costs and diminishing returns on their healthcare investments. The health and well-being of billions of people depend on accelerating drug delivery while reducing development costs. Revolutionizing clinical development requires collaboration among stakeholders who are not accustomed to working together. For governments, this is not only a moral imperative but also a financial one: they cannot afford not to do so. For pharmaceutical companies, too, the stakes are existential. As pipelines grow more complex, blockbusters become rarer and governments take more assertive steps to control drug costs, finding more efficient pathways to secure drug approvals is paramount. And for patients, what is at stake is nothing short of access to the life-saving treatments of tomorrow. Intelligent Clinical Trials: Using Generative AI to Fast-Track Therapeutic Innovations 15